suppression was dependent on the dose of siRNA-expressing pDNA and the time at which transgene expression was determined following simultaneous injection of siRNA-expressing and target pDNAs. A reduction in transgene expression became apparent at 1 day after injection, while a lower degree of inhibition was obtained before this, as early as 6 hr even in mice treated with an excess of siRNA-expressing pDNA. These results suggest that delivery of siRNA-expressing pDNA requires a period of time for induction of RNAi. A study of sequential injections revealed that prior injection of siRNA-expressing pDNA produced a significant suppression for at least 1 day, which disappeared within 4 days.
Confocal microscopic studies indicated that the localization of the cells with successful delivery of transgene was different between primary and secondary hydrodynamics-based injections, accounting for the less effective inhibition following the sequential injections. 4 RNA interference (RNAi) is known as a powerful tool for posttranscriptional gene silencing and expected to be involved in gene therapy strategies (Dykxhoorn et al., 2003; Hannon, 2002; Hutvagner and Zamore, 2002) . Small interfering RNA (siRNA), generated via cleavages of long double-stranded RNA by a member of the RNase III family, Dicer, and typically consisting of two 21-to 23-nucleotide single-stranded RNAs that form a duplex with 2-to 4-nucleotide 3' overhangs, plays a pivotal role in the RNAi process. Application of RNAi to mammals remained limited due to a sequence-nonspecific gene suppression via the interferon response triggered by long (> 30 nucleotides) double-stranded RNA, until it was shown that the use of synthetic siRNA could induce RNAi in mammalian cells without nonspecific inhibition (Caplen et al., 2001; Elbashir et al., 2001) . Immediately after the reports of successful induction of RNAi in mammalian cells, we and other groups (Brummelkamp et al., 2002; Kawasaki and Taira, 2003; Lee et al., 2002; Miyagishi and Taira, 2002; Paddison et al., 2002a; Paul et al., 2002; Sui et al., 2002; Yu et al., 2002 ) developed a vector-based siRNA expression system driven by Pol III promoter such as U6, H1 or transfer RNA val promoter and demonstrated effective induction of vector-based RNAi. Although synthetic siRNA is a functional molecule by itself which can be incorporated into the RNAi-inducing silencing complex (RISC) and can guide RISC to the target mRNA of a complementary sequence, direct application of siRNA is accompanied by several disadvantages including an immediate disappearance of the knockdown effect due to the lack of siRNA amplification mechanisms in mammalian cells (Chiu and Rana, 2002; Stein et al., 2003; Zamore, 2002; Zeng and Cullen, 2002) , difficulty in regulating its activities, and the inconvenience and high expense associated with its use. On the contrary, siRNA-expressing vector, which works as a platform to produce a large amount of siRNA for a relatively longer period, can potentially circumvent these problems and is a versatile method of application of RNAi.
This article has not been copyedited and formatted. The final version may differ from this version. (Makimura et al., 2002) and for vascular endothelial growth factor in the eyes (Reich et al., 2003) . Intraperitoneal delivery of siRNA/lipid-based transfection reagent complexes resulted in suppression of endogenous β-catenin gene expression in grafted colon cancer cells (Verma et al., 2003) and inhibition of lipopolysaccharide-induced TNF-α gene overexpression (Sorensen et al., 2003) . Successful results involving in vivo gene silencing of endogenous targets were achieved predominantly by use of synthetic siRNA. On the other hand, in vivo gene silencing with siRNA-expressing vector has been restricted to topical application (Makimura et al., 2002) or targeting transgenes such as luciferase gene (Lewis et al., 2002; McCaffrey et al., 2002a ) and hepatitis B virus mRNA (McCaffrey et al., 2003) , apart from a reduction in the endogenous β-glucuronidase mRNA level by adenovirus vector-mediated siRNA delivery (Xia et al., 2002) . The delayed success of nonviral vector-based approaches might be attributed in part to the lack of information about vector-based in vivo RNAi. Therefore, in the present study, The purity was checked by agarose gel electrophoresis followed by ethidium bromide staining. procedure (Liu et al., 1999) where the described amount of pDNAs dissolved in 1.6 ml (unless otherwise mentioned) saline were injected into the tail vein over less than 5 sec using a 26-gauge needle.
Mice and intravenous injection
Luciferase assay To determine luciferase activities, mice underwent euthanasia at the indicated time and the organs including the liver, kidney, lung, and muscle were excised and homogenized in 5 ml/g (liver and muscle) or 4 ml/g (kidney and lung) lysis buffer (0.1M Tris, 0.05% Triton X-100, 2mM EDTA, pH 7.8). The homogenate was subjected to three cycles of freezing (-190°C) and thawing (37°C) and centrifuged at 13,000×g for 10 min at 4°C.
Then, appropriately diluted supernatant was mixed with luciferase assay buffer 9 correct for differences in transfection efficiency among mice. The ratios were normalized to give % values relative to those of the corresponding control mice. We set the dose of pGL3-control and pRL-SV40 for the raw values of the luciferase activities to be always at least 10-fold higher than those of the background derived from the liver homogenate of mice without injection. shown). It was also revealed that pU6-tandem26 which expresses a longer RNA duplex of 26 nucleotides was superior in inhibitory activity to the pU6-tandem19 which expresses a 19-nucleotide RNA duplex under these experimental conditions (Fig. 1 ). Since pU6-stem21 which generates the shorter 21-nucleotide RNA duplex appeared more effective than tandem-type siRNA-expressing pDNAs, we used pU6-stem21 as a model siRNA-expressing vector throughout the following studies.
Confocal microscopic study of liver sections

Vector-based RNAi in a variety of tissues following simultaneous injection of siRNA-expressing and target pDNAs
We examined if transgene suppression was obtained in vivo in a variety of tissues by systemic or local delivery of siRNA-expressing pDNA. Fig. 2 shows the inhibitory effect of siRNA-expressing pDNA on transgene expression of the exogenous firefly luciferase gene.
In this set of experiment, we used a higher amount of each pDNA to obtain enough luciferase activities for an accurate analysis in the kidney or lung, based on the fact that the level of transgene expression in these organs is approximately 5-to 6-order of magnitude lower than that in the liver following the hydrodynamics-based procedure (Kobayashi et al., 2002; Liu This article has not been copyedited and formatted. The final version may differ from this version. , 1999) . As a result, a marked reduction of transgene expression was observed in various organs, predominantly in the liver, following intravenous injection of the pDNAs (Fig.   2 ). RNAi-induced transgene suppression also occurred in the muscle following intramuscular injections (Fig. 2) .
Dose-and time-dependent transgene suppression in vector-based in vivo RNAi
To examine any dose-dependence in the suppressive effect in vector-based RNAi, we injected into mice increasing amounts of effector pDNA (pU6-stem21) and a fixed amount of target pDNAs (pGL3-control and pRL-SV40) and determined the degree of transgene suppression after 3 days. As shown in Fig. 3 , inhibitory effect was clearly correlated with the dose of effector pDNA injected, with 97% inhibition in mice treated with 100 µg pU6-stem21. We further investigated the transgene suppression of siRNA-expressing pDNA at different times after simultaneous injection of effector and target pDNAs. A marked suppression (more than 90%) of transgene expression was obtained from day 1 to day 11 after injection (Fig. 4) . However, in the earlier period, only a weak inhibitory effect was seen at 6 hr after injection. To examine if a suppressive effect becomes apparent even at the earlier period following a reduction in the relative amount of target mRNA, we injected into mice a fixed amount of effector pDNA and decreasing amounts of target pDNAs and determined the luciferase activities as early as 6 hr after injection. As a result, a dose-dependent decrease in the Pp-Luc + /Rr-Luc value was observed while the suppression was limited to 50% inhibition at most in mice injected with 0.001 µg target pDNA (Fig. 5) .
Duration of interfering activity following hydrodynamics-based delivery of siRNA-expressing vector
To estimate the duration of suppressing effect of siRNA-expressing pDNA injection, we performed a study of sequential hydrodynamics-based injections of siRNA-expressing pU6-stem21 followed by target pGL3-control and internal control pRL-SV40 at various time intervals. Fig. 6 shows the inhibitory effect of siRNA-expressing pDNA injected at various timepoints before the target pDNA, and in each case, transgene expression was determined at 6 hr after the target pDNA injection. The Pp-Luc + /Rr-Luc values were reduced in mice following 6 hr-or 1 day-prior injection of pU6-stem21, but not in mice following 4 day-or 11 day-prior injection (Fig. 6 ).
Difference in localization of transgene-expressing cells following simultaneous or sequential hydrodynamics-based delivery of pDNAs
To examine the intrahepatic localization of the transgene-expressing cells following the hydrodynamics-based procedure, we injected mice with green fluorescent protein (GFP)-expressing pDNA and/or red fluorescent protein (DsRed)-expressing pDNA. Fig. 7 shows the results of confocal microscopic observation of the liver sections. A simultaneous delivery of pEGFP-N1 and pDsRed-N1 resulted in almost complete overlap of the green and the red signals in the identical cells (Fig. 7A) , while both GFP and DsRed double-positive cells were very rare following the sequential delivery of pEGFP-F and pDsRed-N1 (Fig. 7B ).
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stem-loop-type). Comparative study revealed that both stem-loop-and tandem-type
siRNA-expressing pDNAs were active in vivo, while the stem-loop-type pDNA produced more potent suppression than the tandem-type pDNAs (Fig. 1) . This indicates that, in spite of the requirement of Dicer processing steps, stem-loop-structured siRNA is more suitable in vivo at least in the liver following the hydrodynamics-based delivery, although additional investigations are needed to determine the optimal siRNA-expressing vector involving modified loop sequences and functional elements in the vector construct.
Intravenous injection of pU6-stem21 by the hydrodynamics-based procedure resulted in significant suppression of the target transgene expression in organs including the liver, kidney and lung (Fig. 2) . Because the liver is the organ with the highest transgene expression level following the hydrodynamics-based procedure (Kobayashi et al., 2002; Liu et al., 1999) , an obvious inhibitory effect was observed in the liver. Intramuscular delivery of pU6-stem21 also caused a dramatic reduction (Fig. 2) . These results indicate that RNAi is achieved in and muscle in addition to the liver, as shown in a report involving synthetic siRNA-derived RNAi in a variety of organs in mice (Lewis et al., 2002) . Furthermore, we found a distinct dose-response in the RNAi-induced transgene suppression (Fig. 3 ). An apparent increase in
Pp-Luc
+ /Rr-Luc values in mice treated with the lowest dose of pU6-stem21 is probably due to a difference in the availability or stability of pGL3-control and pRL-SV40 in mice injected with 100 µg or 1 µg pU6 vector. This speculation can be supported by the experimental data showing that injection of different amounts of pGL3-control and pRL-SV40 in a fixed ratio did not result in a constant Pp-Luc + /Rr-Luc value (data not shown).
It was revealed that a reduction in transgene expression became apparent at day 1 after simultaneous injection and remained thereafter, while only a slight inhibition was obtained before this (Fig. 4) . In addition, the transgene suppression determined at 6 hr was limited to 50% inhibition at most, even in mice treated with an effector:target pDNA ratio of 10000:1 (w:w) (Fig. 5) .
On the contrary, an effector:target pDNA ratio of approximately 33:1 or 3:1 (w:w) resulted in a very marked suppression when it was determined on 3 days after injection (Fig. 3) . These results suggest that it requires a specific period until the suppressive effect becomes apparent following simultaneous injection of effector and target pDNAs. We assumed two possible reasons for the delayed appearance of the transgene suppression. Firstly, for cleavage of target mRNA, an injection of siRNA-expressing pDNA requires many steps, such as cellular uptake and nuclear localization of the injected pDNA, transcription of encoded RNA in the downstream of U6 promoter, transport of the RNA to the cytosol, processing by Dicer to produce functional siRNAs, and incorporation of the siRNAs to RISC, even if the hydrodynamics-based procedure produces rapid intracellular delivery of pDNA through the cellular membrane (Kobayashi et al., 2001; submitted for publication.). Secondly, since we introduced the target mRNA-expressing pDNA exogenously along with the effector pDNA, the expression of target mRNA was and target pDNAs. It might be possible that the observed 11-day persistence of transgene suppression does not represent the actual duration of inhibitory effect but is simply due to a significant inhibition achieved at earlier timepoint (Fig. 4) . Therefore, to estimate the duration of provision of active siRNA following siRNA-expressing pDNA injection, we performed sequential hydrodynamics-based injections of effector pDNA followed by target pDNAs. Transgene expression was markedly suppressed by 6 hr-or 1 day-prior injection of pU6-stem21, but not by 4 day-or 11 day-prior injection, indicating that the siRNA remained active and sufficient for transgene suppression for at least 1 day after siRNA-expressing pDNA injection under the present experimental conditions (Fig. 6 ).
Since siRNA-expressing pDNA was delivered beforehand and probably had a sufficiently long period for the required processes, including the transcription and processing of targeted siRNA, the suppressive effect could be obtained as early as 6 hr after target pDNA injection ( Fig. 6 ; 6 hr and 1 day). However, the degree of transgene suppression seemed to be lower To address these differences in the efficacy of transgene suppression between the ways of siRNA-expressing pDNA injection, we examined the localization of the transgene-expressing cells following the hydrodynamics-based procedure. It was found that a sequential delivery of the GFP-expressing and DsRed-expressing pDNAs tended to give the green or the red signals to separated cells (Fig. 7) , indicating that the localization of transgene-expressing cells of the primary and the secondary pDNA injections by the hydrodynamics-based procedure was apparently different. Thus, it seems that, unlike the case of endogenous targets, simultaneous injection does not affect the transfection efficiency in terms of its suppressive effect since the effector and target pDNAs are supposed to be delivered to identical cells . Moreover, the different hepatic localization of the effector and the target pDNAs, which were injected separately, accounts for the lower inhibitory effect in the sequential injection experiment shown in Fig. 6 . In other words, suppression of transgene expression was obtained in only a fraction of the cells where both the siRNA-expressing pDNA and the target pDNAs were delivered, resulting in an apparently lower inhibition. This different localization of transgene positive cells further implies that a study of siRNA-mediated gene therapy in transgene-derived animal models for viral infections, in which hepatitis B, C or D viral genomic DNA or RNA was introduced by the hydrodynamics-based procedure (Chang et al., 2001; McCaffrey et al., 2002b; Yang et al., 2002) , should take the delivery efficiency into account.
In addition to their lower cost of production, vector-based approaches for induction of in vivo RNAi have a number of potential advantages including the possibility of sustained gene silencing and regulation of siRNA expression. The U6 promoter could be controlled with respect to its activity to transcribe RNAs by modification of the promoter to a tetracycline-responsive derivative (Ohkawa and Taira, 2000; Taira and Miyagishi, 2001 ). Significantly different from the corresponding control; * P < 0.05, ** P < 0.01. Mice received an intravenous injection of the indicated dose of pU6-stem21, pGL3-control (3 µg) and pRL-SV40 (3 µg) by the hydrodynamics-based procedure. Control mice were injected with piGENE TM hU6 (100 µg), pGL3-control (3 µg) and pRL-SV40 (3 µg).
Luciferase activities in the liver were determined 3 days after injection. The results are expressed as the mean ± S.D. (n>3). Then, at the indicated times, mice were injected again with target pDNAs, pGL3-control (0.01 µg) and pRL-SV40 (0.1 µg), by the hydrodynamics-based procedure in a volume of 1.6 ml (6 hr and 1 day), 2.7 ml (4 days) or 3.2 ml (11 days). Luciferase activities in the liver were determined 6 hr after injection of target pDNAs. The results are expressed as the mean ± S.D. (n>3). * P < 0.05. 
